Methods of using propionoyloxymethyl propionate ("POMP") and butyroyloxymethyl butyrate ("BOMB") are disclosed. Methods of treating cancer using these compounds are disclosed. The compounds are effective in the inhibition of histone deacetylase.

Esters of acyl L-carnitine with gamma-hydroxybutyric acid, both as pharmacologically acceptable salts of formula (1) ##STR1## and as inner salts of formula (1') ##STR2## wherein X.sup.- is the anion of a pharmacologically acceptable acid and R is a straight or branched acyl group having from 2 to 5 carbon atoms, are used for producing pharmaceutical compositions effective for treating hepatopathies.

3-methylthiopropionyl L-carnitine and its pharmacologically acceptable salts are active on the cardiovascular system, particularly in the treatment of myocardial anoxia, cardiac ischaemia, arrhythmias and congestive heart failure.

Methods and compositions are provided for treating selected bacterial infections wherein the anti-bacterially active ingredient is a compound of the following formula: ##STR1## wherein R' and R" are each independently a straight chain or branched chain alkyl group having from 5 to 8 carbon atoms, M is NH.sub.4, Na, K or Ca, and x is 1 when M is Na, K or NH.sub.4, and x is 2 when M is Ca.

The use of an alkanoyl-L-carnitine, e.g., acetyl-L-carnitine, or a pharmacologically acceptable salt thereof is disclosed to produce a medicament for the therapeutic treatment or prophylaxis of glutamate-mediated cytological disturbances or diseases.

A therapeutical method for treating chronic arteriosclerosis obliterans in particularly selected patients with severely disabling intermittent claudication is disclosed, which comprises administering propionyl L-carnitine or a pharmacologically acceptable salts thereof.

This invention relates to the use of butyrate prodrugs derived from lactic acid for treating inflammatory bowel disease. The invention also relates to the use of those prodrugs for the treatment of a chemotherapy-induced mucocutaneous side effect in a patient. The invention further relates to the use of butyrate prodrugs for treating lung, colo-rectal or prostate cancer. And the invention also relates to the use of butyrate prodrugs to treat cystic fibrosis and to enhance the efficiency of gene ...

Carnitine, which preferentially accumulates in cardiac and skeletal muscle, is coupled to a protease inhibitor, or any other pharmaceutically active compound for the purpose of site-specific drug delivery to these tissues. These products may be useful in a variety of muscle wasting diseases. They may also be useful in a variety of cardiac conditions including those produced by cardiac ischemia. They may also be useful as growth promoters for animals.

This invention relates to butyrate prodrugs derived from lactic acid and pharmaceutical compositions and methods employing them, either alone or in combination with other agents, for increasing gamma globin and fetal hemoglobin in a patient. These compounds, compositions and methods are particularly effective in treating .beta.-hemoglobinopathies, including sickle cell syndromes and .beta.-thalassemia syndromes. In addition, this invention relates to the use of these prodrugs, alone or in combin...

This invention relates to butyrate prodrugs derived from lactic acid and pharmaceutical compositions and methods employing them, either alone or in combination with other agents, for increasing gamma globin and fetal hemoglobin in a patient. These compounds, compositions and methods are particularly effective in treating .beta.-hemoglobinopathies, including sickle cell syndromes and .beta.-thalassemia syndromes. This invention relates to the use of these prodrugs, alone or in combination with ot...